Spruce Biosciences Strengthens Medical Leadership Ahead of Potential TA-ERT Approval
Event summary
- Spruce Biosciences appointed Agnieszka Jurecka, M.D., Ph.D., MPH as Vice President of Medical Affairs on June 22, 2026.
- Dr. Jurecka brings over 20 years of experience in rare disease drug development and medical affairs, with expertise in enzyme replacement therapies and lysosomal storage disorders.
- She was granted restricted stock units (RSUs) for 3,800 shares of Spruce’s common stock, vesting over four years.
- Spruce's lead product candidate, TA-ERT, is in late-stage development for Sanfilippo Syndrome Type B.
The big picture
Spruce Biosciences is positioning itself for a critical phase in its development, with the appointment of Dr. Jurecka signaling a focus on strengthening medical affairs and scientific engagement ahead of a potential TA-ERT approval. This move comes as the company aims to address significant unmet medical needs in neurological disorders, particularly Sanfilippo Syndrome Type B, where no FDA-approved therapies currently exist.
What we're watching
- Regulatory Timeline
- Whether Spruce can secure U.S. approval for TA-ERT in 2027 as anticipated.
- Launch Readiness
- How effectively Dr. Jurecka can establish disease awareness and build key opinion leader (KOL) relationships ahead of the potential launch.
- Strategic Fit
- The impact of Dr. Jurecka's extensive experience in rare diseases on Spruce's ability to navigate regulatory and commercial challenges.